Last reviewed · How we verify
Antibiotic (Amoxicillin)
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking peptidoglycan cross-linking.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking peptidoglycan cross-linking. Used for Bacterial infections (respiratory tract, urinary tract, skin and soft tissue, otitis media, sinusitis), Helicobacter pylori eradication (as part of combination therapy).
At a glance
| Generic name | Antibiotic (Amoxicillin) |
|---|---|
| Sponsor | Norwegian University of Science and Technology |
| Drug class | Beta-lactam antibiotic (aminopenicillin) |
| Target | Penicillin-binding proteins (PBPs); bacterial peptidoglycan |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Amoxicillin is a beta-lactam antibiotic that penetrates bacterial cell walls and irreversibly binds to penicillin-binding proteins (PBPs), preventing the cross-linking of peptidoglycan strands. This disrupts cell wall integrity, leading to bacterial cell lysis and death. It is bactericidal and effective against a broad spectrum of gram-positive and some gram-negative bacteria.
Approved indications
- Bacterial infections (respiratory tract, urinary tract, skin and soft tissue, otitis media, sinusitis)
- Helicobacter pylori eradication (as part of combination therapy)
Common side effects
- Diarrhea
- Nausea
- Rash
- Allergic reaction / Anaphylaxis
- Vomiting
- Abdominal pain
Key clinical trials
- Immediate Restoration of a New Implant With High Primary Stability (NA)
- APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis) (PHASE2)
- Fast Track Therapeutic Model in Acute Complicated Appendicitis in Pediatrics (PHASE4)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing (PHASE2)
- Antibiotyping and Prevalence of Virulent Genotypes Among Helicobacter Pylori and Their Impact on Response to Therapy (NA)
- Effect of Antibiotics on Enteric Neurons and Glia (PHASE4)
- Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |